共 50 条
- [31] A PHASE 1 STUDY OF IMC-001, A PD-L1 BLOCKER, IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A176 - A176Keam, BhumsukKim, Tae MinOh, Do-YounOck, Chan-YoungKang, Won KiPark, Yeon HeeLee, JeeyunLee, Ji HyeSong, Yun JeongPark, Young Suk
- [32] A phase 1 study of oral navelbine in patients with advanced solid tumors.CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6137S - 6137SRajdev, LDai, QMani, SGoldberg, GBaker, CHoschander, SSparano, J
- [33] Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1436Prenen, H.Kyi, C.Van Lancker, G.Patel, S. P.Mittag, D.Weaver, A.Bol, K.Stalbovskaya, V.Pulini, J.Zhou, G.Dong, Z.Asatiani, E.Hodi, F. S.
- [34] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid TumorsCANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265Muik, AlexanderGarralda, ElenaAltintas, IsilGieseke, FriederikeGeva, RavitBen-Ami, EytanMaurice-Dror, CorinneCalvo, EmilianoLoRusso, Patricia M.Alonso, GuzmanRodriguez-Ruiz, Maria E.Schoedel, Kristina B.Blum, Jordan M.Sanger, BiancaSalcedo, Theodora W.Burm, Saskia M.Stanganello, ElianaVerzijl, DennisVascotto, FulviaSette, AngelicaQuinkhardt, JulianePlantinga, Theo S.Toker, Arasvan den Brink, Edward N.Fereshteh, MarkDiken, MustafaSatijn, DavidKreiter, SebastianBreij, Esther C. W.Bajaj, GauravLagkadinou, EleniSasser, KateTureci, OzlemForssmann, UlfAhmadi, TahamtanSahin, UgurJure-Kunkel, MariaMelero, Ignacio
- [35] A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lin, TongyuLiu, BinPu, XingxiangWu, LinDu, XiaoboMo, NingSong, ZhengboZhou, LiweiDuan, XianlinZhu, YananKang, Xiaoyan
- [36] PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial TumorsCUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (12)Wang, Jaeyun JaneBurger, PeterTaube, JanisSoni, AbhaChaichana, KaisornSheu, MaryBelcaid, ZinebJackson, ChristopherLim, Michael
- [37] Patterns of PD-1 PD-L1 and PD-L2 expression in pediatric solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Pinto, Navin R.Park, Julie R.Murphy, ErinYearley, JenniferMcClanahan, TerriAnnamalai, LakshmananHawkins, Douglas S.Rudzinski, Erin R.
- [38] Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Iguchi, HaruoNogami, NaoyukiKozuki, ToshiyukiMatsumoto, ToshihikoTamura, KenjiYamamoto, NoboruShimomura, AkihikoHoshino, YujiMichibata, YoshikoNii, MasahiroFujiwara, Yutaka
- [39] A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Infante, Jeffrey R.Hansen, Aaron RichardPishvaian, Michael J.Chow, Laura Quan ManMcArthur, Grant A.Bauer, Todd MichaelLiu, Stephen V.Sandhu, Shahneen KaurTsai, Frank Yung -ChinKim, JeongStefanich, EricLi, Chi -ChungGilber, HoustonMccall, BruceAnderson, Maria S.Huseni, MahrukhRhee, Ina ParkSiu, Lillian L.Gordon, Michael S.